Research programme: T-cell recruiting therapeutics - Harpoon Therapeutics

Drug Profile

Research programme: T-cell recruiting therapeutics - Harpoon Therapeutics

Alternative Names: HPN 424

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Harpoon Therapeutics
  • Class Antineoplastics; Immunotherapies; Trispecific antibodies
  • Mechanism of Action Glutamate carboxypeptidase II modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 18 Oct 2017 Harpoon Therapeutics and AbbVie agree to co-develop T-cell recruiting therapeutics for Cancer
  • 26 Jan 2017 Preclinical trials in Prostate cancer in USA (Parenteral)
  • 26 Jan 2017 Harpoon Therapeutics plans a phase I trial for prostate cancer, in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top